Clinical studies recruiting near Anderlecht

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Observational Study Protocol: LIVER-R
Phase N/A · AstraZeneca · NCT06252753 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · Institut Jules Bordet · Pfizer · NCT07028853 Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY)
Phase 3 · Hopital Erasme · NTC srl · NCT07465705 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · Jules Bordet lnstitute · Miltenyi Biomedicine GmbH · NCT04844866 A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · Institut Jules Bordet · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762 Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 · INSTITUT JULES BORDET - Service Hématologie · The Lymphoma Academic Research Organisation · NCT06006117 Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/Phase 2 · Institut Jules Bordet · OSE Immunotherapeutics · NCT05751798 Effect of IMT in Patients After Acute Exacerbations of COPD
NA · Campus Joseph Bracops, Hôpitaux Iris Sud · KU Leuven · NCT07213128 Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · Institut Jules Bordet · European Organisation for Research and Treatment of Cancer - · NCT04498767 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Institut Jules Bordet /ID# 246770 · AbbVie · NCT04928846 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Institut Jules Bordet · Daiichi Sankyo · NCT06731478 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · Research Site · AstraZeneca · NCT06692738 Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC Wi
Phase 3 · Research Site · AstraZeneca · NCT06357533 A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of C
Phase 3 · Institut Jules Bordet /ID# 279406 · AbbVie · NCT07525206 A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre
Phase 3 · Investigative Site BE008 · Incyte Corporation · NCT07522073 First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant
Phase 1 · Institut Jules Bordet / Nuclear Medicine · Bayer · NCT06217822 A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours
NA · Institut Jules Bordet · Jules Bordet Institute · NCT04109131 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/Phase 2 · Research Site · AstraZeneca · NCT05123482 Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Phase 1/Phase 2 · Institut Jules Bordet · Immunocore Ltd · NCT06840119 A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Met
Phase 1/Phase 2 · Institut Jules Bordet · Janssen Research & Development, LLC · NCT05379595 A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase N/A · Institut Jules Bordet · Swedish Orphan Biovitrum · NCT05776472 A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Phase 2 · Site BE32009 · Astellas Pharma Global Development, Inc. · NCT02960022 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · Institut Jules Bordet · Revolution Medicines, Inc. · NCT06881784 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherap
Phase 2/Phase 3 · Institut Jules Bordet /ID# 277283 · AbbVie · NCT07155187 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Institut Jules Bordet ( Site 2903) · Merck Sharp & Dohme LLC · NCT03486873 PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (
NA · Institut Jules Bordet · European Organisation for Research and Treatment of Cancer - · NCT04790253 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · Institut Jules Bordet · Hoffmann-La Roche · NCT05894239 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar
Phase 3 · Institut Jules Bordet · Janssen Research & Development, LLC · NCT05552222 Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 202
Phase N/A · Institut Jules Bordet · European Organisation for Research and Treatment of Cancer - · NCT05259605

Look up another city

Look up another condition